Story preview
Continue reading on the publisher site for the full article.
Read on publisher →Yahoo Finance
News Atlas is free and independent. If it’s useful to you, you can support it with a coffee. ☕ Buy me a coffee
Coverage
Tone
Outlets covering it
8
in the last 3 days
First reported
2 days ago
7 outlets since
Countries
7 other outlets reported this story in the last 3 days.
Eli Lilly (LLY) is likely to post a strong volume growth in Q3 that is expected to outweigh pricing
Eli Lilly trades at a premium multiple, yet its revenue growth dwarfs every major pharma peer by a wide margin. Whether that gap justifies buying shares near all-time highs depends on one critical assumption about Lilly's pipeline.
Eli Lilly is the powerhouse behind today’s blockbuster drugs Mounjaro (tirzepatide), prescribed for weight loss; erectile-dysfunction treatment Cialis (tadalafil); Humalog, a rapid-acting insulin; and diabetes treatment Trulicity. Founded in 1876 by Civil War veteran Eli Lilly, it was the first to mass-produce insulin…